PTC Therapeutics (PTCT) News Today → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free PTCT Stock Alerts $36.36 +0.55 (+1.54%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29, 2024 | prnewswire.comPTC Therapeutics to Participate at Upcoming Investor ConferenceMay 29, 2024 | americanbankingnews.comThe Goldman Sachs Group Increases PTC Therapeutics (NASDAQ:PTCT) Price Target to $32.00May 28, 2024 | finanznachrichten.dePTC Therapeutics, Inc.: PTC Therapeutics Announces Validation of Sepiapterin European MAAMay 28, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Price Target Increased to $32.00 by Analysts at The Goldman Sachs GroupThe Goldman Sachs Group lifted their price objective on shares of PTC Therapeutics from $18.00 to $32.00 and gave the company a "sell" rating in a report on Tuesday.May 28, 2024 | prnewswire.comPTC Therapeutics Announces Validation of Sepiapterin European MAAMay 26, 2024 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Director Sells $764,800.00 in StockMay 25, 2024 | insidertrades.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Sells 20,000 Shares of StockMay 25, 2024 | finance.yahoo.comInsider Sale: Director Jerome Zeldis Sells 20,000 Shares of PTC Therapeutics Inc (PTCT)May 23, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for PTC Therapeutics, Inc. Issued By William Blair (NASDAQ:PTCT)May 23, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for PTC Therapeutics, Inc. Decreased by Leerink Partnrs (NASDAQ:PTCT)May 22, 2024 | marketbeat.com232,663 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Acquired by Trexquant Investment LPTrexquant Investment LP purchased a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 232,663 shares of the biopharmaceutical company's stock, valued at approximately $6,412,000May 22, 2024 | seekingalpha.comPTC Therapeutics: Riding The Regulatory Rollercoaster With TranslarnaMay 22, 2024 | markets.businessinsider.comHold Rating on PTC Therapeutics Amid Regulatory Uncertainty for TranslarnaMay 22, 2024 | marketbeat.comPTC Therapeutics, Inc. Forecasted to Post Q2 2024 Earnings of ($1.02) Per Share (NASDAQ:PTCT)PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Leerink Partnrs lowered their Q2 2024 earnings estimates for shares of PTC Therapeutics in a note issued to investors on Sunday, May 19th. Leerink Partnrs analyst J. Schwartz now anticipates that the biopharmaceutical company will post earningsMay 21, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Given New $26.00 Price Target at CitigroupCitigroup lifted their price objective on shares of PTC Therapeutics from $18.00 to $26.00 and gave the company a "sell" rating in a report on Tuesday.May 20, 2024 | markets.businessinsider.comSell Rating Maintained for PTC Therapeutics Amid Long-Term Revenue Growth ConcernsMay 20, 2024 | markets.businessinsider.comTranslarna’s Uncertain Future: Justifying a Sell Rating for PTC TherapeuticsMay 20, 2024 | marketbeat.comJefferies Financial Group Increases PTC Therapeutics (NASDAQ:PTCT) Price Target to $46.00Jefferies Financial Group boosted their price target on PTC Therapeutics from $35.00 to $46.00 and gave the company a "buy" rating in a report on Monday.May 20, 2024 | finanznachrichten.dePTC Therapeutics, Inc.: PTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluationMay 20, 2024 | marketwatch.comPTC Therapeutics Shares Rise 21% After European Commission Declines CHMP Opinion on TranslarnaMay 20, 2024 | msn.comPTC Therapeutics rallies 18% on EU authorization update for TranslarnaMay 20, 2024 | msn.comEuropean Commission Requests Reevaluation Of Opinion On PTC Therapeutics' Duchenne Dystrophy Drug; Pauses Annual GuidanceMay 20, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Shares Gap Up to $33.10PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up to $33.10May 20, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Upgraded at Raymond JamesRaymond James raised shares of PTC Therapeutics from an "underperform" rating to a "market perform" rating in a research report on Monday.May 20, 2024 | marketwatch.comPTC Therapeutics Pauses 2024 Revenue Guidance After European Commission Requests Reevaluation of Opinion on ApprovalMay 20, 2024 | markets.businessinsider.comPTC Therapeutics Says European Commission Returns Translarna Opinion To CHMP For Re-evaluationMay 20, 2024 | prnewswire.comPTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluationMay 17, 2024 | marketbeat.comBNP Paribas Financial Markets Increases Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)BNP Paribas Financial Markets lifted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 263.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 371,580 shares of the biopharMay 14, 2024 | marketwatch.comPTC Therapeutics Gets FDA Priority Review of Upstaza Gene TherapyMay 14, 2024 | prnewswire.comPTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™May 10, 2024 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Position Trimmed by Russell Investments Group Ltd.Russell Investments Group Ltd. trimmed its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 13.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 191,120 shares of the biopharmaceutical company's stock afMay 9, 2024 | seekingalpha.comPTCT PTC Therapeutics, Inc.May 2, 2024 | prnewswire.comPTC Therapeutics to Participate at Upcoming Investor ConferencesMay 1, 2024 | finance.yahoo.comPTC Therapeutics Stock Sees IBD RS Rating Climb To 72April 29, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Trading 6.1% Higher PTC Therapeutics (NASDAQ:PTCT) Trading Up 6.1%April 29, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Upgraded at Morgan StanleyMorgan Stanley upgraded PTC Therapeutics from an "underweight" rating to an "equal weight" rating and boosted their price objective for the stock from $28.00 to $30.00 in a research note on Monday.April 28, 2024 | finance.yahoo.comIndustry Analysts Just Made A Captivating Upgrade To Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue ForecastsApril 27, 2024 | seekingalpha.comPTC Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call TranscriptApril 26, 2024 | finance.yahoo.comSector Update: Health Care Stocks Edge Higher Late AfternoonApril 26, 2024 | finance.yahoo.comPTC Therapeutics Inc (PTCT) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ...April 26, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Shares Gap Up Following Better-Than-Expected EarningsPTC Therapeutics (NASDAQ:PTCT) Shares Gap Up on Better-Than-Expected EarningsApril 25, 2024 | investorplace.comPTCT Stock Earnings: PTC Therapeutics Beats EPS, Beats Revenue for Q1 2024April 25, 2024 | prnewswire.comPTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsApril 23, 2024 | prnewswire.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 23, 2024 | insidertrades.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells 3,361 Shares of StockApril 22, 2024 | marketbeat.comMatthew B. Klein Sells 3,361 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CEO Matthew B. Klein sold 3,361 shares of the firm's stock in a transaction dated Friday, April 19th. The stock was sold at an average price of $24.89, for a total transaction of $83,655.29. Following the completion of the transaction, the chief executive officer now directly owns 225,807 shares in the company, valued at $5,620,336.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.April 21, 2024 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Knights of Columbus Asset Advisors LLCKnights of Columbus Asset Advisors LLC lifted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 104.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,424 shares of the biApril 21, 2024 | investing.comPTC Therapeutics CEO sells shares worth over $19kApril 20, 2024 | insidertrades.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells 787 Shares of StockApril 19, 2024 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Eric Pauwels Sells 787 SharesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CEO Eric Pauwels sold 787 shares of the company's stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $25.14, for a total transaction of $19,785.18. Following the completion of the sale, the chief executive officer now directly owns 67,694 shares in the company, valued at $1,701,827.16. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address The only financial event in 2024 that matters (Ad)Man Who Predicted 2008 Crash Warns of Black Swan Financial Event in 2024 Porter Stansberry’s new documentary is going viral. Stream the documentary for free by clicking here PTCT Media Mentions By Week PTCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTCT News Sentiment▼0.870.76▲Average Medical News Sentiment PTCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTCT Articles This Week▼84▲PTCT Articles Average Week Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SAGE News EBS News CTLT News ROIV News ELAN News ASND News LEGN News CERE News VKTX News ITCI News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTCT) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBuy this small stock before coming AI Tidal WaveChaikin AnalyticsWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
